|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
573,600,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$179.79 - $179.79 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Wiezorek Jeffrey |
SVP Clinical Development |
|
2016-03-15 |
4 |
AS |
$44.56 |
$403,943 |
D/D |
(9,000) |
14,867 |
|
- |
|
Wiezorek Jeffrey |
SVP Clinical Development |
|
2016-03-15 |
4 |
OE |
$6.89 |
$62,010 |
D/D |
9,000 |
23,867 |
|
- |
|
Roberts Margo R |
Chief Scientific Officer |
|
2016-03-15 |
4 |
AS |
$45.09 |
$384,766 |
D/D |
(8,506) |
10,655 |
|
- |
|
Roberts Margo R |
Chief Scientific Officer |
|
2016-03-15 |
4 |
OE |
$0.70 |
$22,352 |
D/D |
8,506 |
19,161 |
|
- |
|
Moore Timothy L. |
EVP, Technical Operations |
|
2016-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
50,000 |
|
- |
|
Humer Franz B |
Director |
|
2016-03-10 |
4 |
A |
$0.00 |
$0 |
D/D |
2,071 |
2,071 |
|
- |
|
Butitta Cynthia M |
COO and CFO |
|
2016-03-01 |
4 |
AS |
$50.03 |
$500,300 |
D/D |
(10,000) |
95,401 |
|
- |
|
Butitta Cynthia M |
COO and CFO |
|
2016-03-01 |
4 |
OE |
$1.35 |
$13,500 |
D/D |
10,000 |
105,401 |
|
- |
|
Roberts Margo R |
Chief Scientific Officer |
|
2016-02-17 |
4 |
AS |
$45.05 |
$434,018 |
D/D |
(9,632) |
9,098 |
|
- |
|
Roberts Margo R |
Chief Scientific Officer |
|
2016-02-17 |
4 |
OE |
$0.70 |
$6,742 |
D/D |
9,632 |
18,730 |
|
- |
|
Sproule Rizwana F |
VP Regulatory Affairs |
|
2016-02-17 |
4 |
AS |
$45.07 |
$431,279 |
D/D |
(9,567) |
8,741 |
|
- |
|
Sproule Rizwana F |
VP Regulatory Affairs |
|
2016-02-17 |
4 |
OE |
$1.35 |
$12,915 |
D/D |
9,567 |
18,308 |
|
- |
|
Wiezorek Jeffrey |
SVP Clinical Development |
|
2016-02-16 |
4 |
AS |
$44.00 |
$396,652 |
D/D |
(9,000) |
13,742 |
|
- |
|
Wiezorek Jeffrey |
SVP Clinical Development |
|
2016-02-16 |
4 |
OE |
$6.89 |
$62,010 |
D/D |
9,000 |
22,742 |
|
- |
|
Roberts Margo R |
Chief Scientific Officer |
|
2016-02-12 |
4 |
AS |
$64.16 |
$1,202,964 |
D/D |
(18,750) |
9,098 |
|
- |
|
Roberts Margo R |
Chief Scientific Officer |
|
2016-02-12 |
4 |
OE |
$0.70 |
$13,125 |
D/D |
18,750 |
27,848 |
|
- |
|
Butitta Cynthia M |
COO and CFO |
|
2016-02-02 |
4 |
AS |
$50.13 |
$95,247 |
D/D |
(1,900) |
94,007 |
|
- |
|
Butitta Cynthia M |
COO and CFO |
|
2016-02-02 |
4 |
OE |
$1.35 |
$2,565 |
D/D |
1,900 |
95,907 |
|
- |
|
Better Marc |
VP, Product Sciences |
|
2016-02-01 |
4 |
AS |
$46.50 |
$426,036 |
D/D |
(9,000) |
7,688 |
|
- |
|
Better Marc |
VP, Product Sciences |
|
2016-02-01 |
4 |
OE |
$0.38 |
$3,420 |
D/D |
9,000 |
16,688 |
|
- |
|
Butitta Cynthia M |
COO and CFO |
|
2016-01-27 |
4 |
AS |
$50.42 |
$418,128 |
D/D |
(8,100) |
94,007 |
|
- |
|
Butitta Cynthia M |
COO and CFO |
|
2016-01-27 |
4 |
OE |
$1.35 |
$10,935 |
D/D |
8,100 |
102,107 |
|
- |
|
Sproule Rizwana F |
VP Regulatory Affairs |
|
2016-01-19 |
4 |
AS |
$53.55 |
$155,242 |
D/D |
(2,767) |
8,741 |
|
- |
|
Sproule Rizwana F |
VP Regulatory Affairs |
|
2016-01-19 |
4 |
OE |
$1.35 |
$3,735 |
D/D |
2,767 |
11,508 |
|
- |
|
Wiezorek Jeffrey |
SVP Clinical Development |
|
2016-01-15 |
4 |
AS |
$52.60 |
$497,379 |
D/D |
(9,000) |
13,742 |
|
- |
|
387 Records found
|
|
Page 10 of 16 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|